MetaCap

OPKO Health Inc. (OPK)

NASDAQ: OPKHealth CareBiotechnology: Pharmaceutical PreparationsUSD

1.57-0.04 (-2.48%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OPK stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$0.16
52-week range
0.98 – 1.86
Day range
1.55 – 1.62
Volume / Avg
3.52M / 3.83M
Beta
—

52-week range

$0.98$1.86

OPK stock today

Shares of OPKO Health (OPK) finished lower on Nov 20 at $1.57, a drop of 2.48% or $0.04 per share, versus the S&P 500's 3.70% decline. At this level, OPK sits in the middle of its 52-week range of $0.98 to $1.86: 15.6% below the high, set on Nov 6, 2026 and 60.2% above the low. OPK is up 24.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 18.9%.

OPKO Health has posted a net loss over the last twelve months (EPS of -$0.16), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About OPKO Health

Company profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Phillip Frost M.D., Ph.D.
Headquarters
Miami, FL
Employees
2,275
Website
opko.com

Financial highlights

Full financials

In fiscal 2025, OPKO Health generated $606.9 million in revenue, down 14.9% from fiscal 2024, its first annual decline since 2024. OPKO Health reported a net loss of $225.7 million, compared with a loss of $53.2 million a year earlier. Gross margin was 33.9% (up from 30.6%) and operating margin -19.3%.

OPKO Health annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$606.88M$713.14M$863.50M$1.00B$1.77B
Growth-14.90%-17.41%-14.01%-43.42%+23.64%
Net income$-225.68M$-53.22M$-188.86M$-328.40M$-30.14M
EPS (diluted)$-0.30$-0.08$-0.25$-0.46$-0.05

Analyst forecast

Forecast

Consensus (6 analysts)

buy

Avg. price target

$4.15+164.33%

  • Strong buy 3
  • Buy 2
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $2.25High $8.50

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.07 vs $-0.07

OPK news

All OPK news

OPKO Health peers

Health Care sector
OPK peer companies
CompanyPrice% ChgMarket capCompare
GPCRStructure Therapeutics Inc. ADR16.13-5.78%$1.15Bvs OPK
HROWHarrow Inc.30.41-5.35%$1.14Bvs OPK
CMPSCOMPASS Pathways Plc American Depository Shares8.05-6.94%$1.14Bvs OPK
GHRSGH Research PLC17.53-5.55%$1.20Bvs OPK
AMPHAmphastar Pharmaceuticals Inc.28.25+0.50%$1.20Bvs OPK
MLYSMineralys Therapeutics Inc.13.66-3.53%$1.21Bvs OPK
AAPGAscentage Pharma Group International American Depository Shares11.97-3.78%$1.12Bvs OPK
OCULOcular Therapeutix Inc.5.57-4.95%$1.23Bvs OPK

Indexes, lists and sector

OPKO Health stock FAQ

What is OPKO Health's stock price today?

OPK last traded at $1.57 as of Nov 20, 4:00 PM EST, down 2.48% on the day. Prices are delayed at least 15 minutes.

Who is OPKO Health's CEO?

Dr. Phillip Frost M.D., Ph.D. is the chief executive officer of OPKO Health Inc., which has about 2,275 employees.

What is the OPK 52-week high?

The 52-week high for OPK is $1.86 and the 52-week low is $0.98. The stock is currently 15.6% below its high.

Compare OPK